Today's Daily Dose brings you news about Altimmune's progress in ints intranasal COVID-19 vaccine candidate, Independent Data Monitoring Committee recommending stopping of Celsion's phase III OPTIMA study, FDA refusing to accept for review CytoDyn's Biologics License Application for Leronlimab, multi-fold jump in the share price of Equillium, and promising Alzheimer's trial data of INmune Bio.
from RTT - Biotech https://ift.tt/390UyGf
via IFTTT
No comments:
Post a Comment